BioSpace News Archive

Life Spine, a medical device company that designs, develops, manufactures and markets products for the surgical treatment of spinal disorders, announced today the first surgical cases of ProLift Micro Endoscopic Expandable Spacer System.

Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today that Erica Monaco, Chief Executive Officer, will be presenting and meeting with registered investors at the LD Micro Main Event XV that will be held October 25-27, 2022 at the Luxe Sunset Boulevard Hotel in Southern California.

Clario, a technology company that delivers the leading endpoint solutions for decentralized, hybrid and site-based clinical trials, today published a manuscript in Nature Medicine that outlines how AI can improve patients’ experience in DCTs.

Novavax, Inc. (Nasdaq: NVAX) will present new data from the Phase 3 PREVENT-19 trial evaluating its protein-based COVID-19 vaccine (NVX-CoV2373) as a booster in adults, including a breakdown by age and by booster dose interval (8 and 11 months) at IDWeek 2022, October 20 to 22, 2022.

Cingulate Inc. (NASDAQ: CING) today announced that Cingulate Chairman & CEO Shane J. Schaffer will present at the LD Micro Main Event XV investor conference on October 26, 2022.

Advanced BioScience Laboratories announced it has been awarded a contract for “Preclinical and translational vaccine development for HIV and other candidate agents” by the Division of AIDS within the National Institute of Allergy and Infectious Disease of the National Institutes of Health.

AbbVie (NYSE: ABBV) today announced the acquisition of DJS Antibodies Ltd (“DJS”), a privately-held UK-based biotechnology company dedicated to discovering and developing antibody medicines that target difficult-to-drug disease-causing proteins, such as G protein-coupled receptors (GPCRs).

AstraZeneca, in partnership with Scientific American Custom Media, today announced the winners of the fourth annual Cancer Community Awards (C2 Awards).

RefleXion® Medical, a therapeutic oncology company pioneering biology-guided radiotherapy* (BgRT) as a new modality for treating all stages of cancer, today announced eight clinical abstracts evaluating the potential use and utility of its novel technology were accepted for presentation during the American Society for Radiation Oncology (ASTRO) 2022 Annual Meeting, Oct. 23-26, in San Antonio.

SeqOne Genomics, announced that Michael Blum, Ph.D. is joining the company to lead its research and development department.